Executive Q&A: Thomas Hein, SVP commercial and regulatory affairs, Hermes Pharma

28 July 2014

In an interview with The Pharma Letter, Thomas Hein, senior vice president of commercial and regulatory affairs for German privately-owned company Hermes Pharma, tells us about how the company is working closely with eight of the world's top 15 pharma companies on its user-friendly dosage forms.

Please could you give us an overview of what Hermes Pharma does?

Hermes Pharma is a division of the German pharmaceutical company Hermes Arzneimittel GmbH which was founded more than 100 years ago. We specialize in developing, formulating and manufacturing user-friendly medicines including effervescent and chewable tablets, instant drinks and orally disintegrating granules (ODGs). We have more than 40 years of experience working with Pharma, from product development and manufacturing through to regulatory support and product marketing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK